Hims & Hers Posts $92 Million Loss in Q1 2026 After Ditching Compounded Weight-Loss Drugs for Branded GLP-1s

The Numbers Are Bad. Here's Why.

Hims & Hers Health reported Q1 2026 revenue of $608.1 million — a 4% year-over-year increase, but $8.75 million short of Wall Street's consensus estimate of $616.85 million, according to Stocktwits and TrustFinance.

The real problem: a GAAP net loss of $92 million. Analysts had penciled in a profit of roughly $0.03–$0.04 per share. Instead, the company delivered a $0.40 per share loss.

Shares fell 13% in after-hours trading on May 11, 2026.

What Actually Caused the Loss

This wasn't a business collapsing. It was a business dismantling its own supply chain on purpose.

CFO Yemi Okupe confirmed the loss was driven by non-recurring restructuring charges of approximately $33.5 million — primarily write-downs tied to winding down Hims' compounded GLP-1 supply chain — plus a $15 million legal settlement and additional M&A transaction costs, according to MarketBeat's earnings call coverage.

Hims built a massive operation around compounded semaglutide — the cheaper, pharmacy-mixed version of Ozempic and Wegovy. When the FDA declared the brand-name drugs no longer in shortage, that business model had an expiration date. Hims is now liquidating the inventory and infrastructure it built, and booking the losses now.

This is a strategic decision, not an operational failure. But investors still hate it in the short term.

Gross Margins Got Crushed

Gross margin fell from 73% a year ago to 65% this quarter, according to Stocktwits. That's significant compression for a company that built its valuation on high-margin digital health subscriptions.

Monthly revenue per average subscriber dropped from $85 to $80 — down 6% year-over-year — even as subscriber count grew 9% to nearly 2.6 million. More customers, less money per customer.

The Pivot: Branded GLP-1s and the Novo Nordisk Bet

Hims is betting its future on a direct partnership with Novo Nordisk, the Danish pharma giant that makes Wegovy and Ozempic. The strategy: stop selling compounded knockoffs and become an authorized distribution channel for FDA-approved branded treatments.

It's a complete reversal. For years, Hims' pitch was giving consumers cheaper access to weight-loss drugs through compounding pharmacies. Now they're selling the expensive branded version — which means lower margins and higher costs, at least until scale kicks in.

CEO Andrew Dudum called 2026 "a year of accelerating growth" on the earnings call, per MarketBeat. He pointed to new U.S. specialties, international expansion, and technology investment as growth drivers.

The company also announced the acquisition of Eucalyptus, an international telehealth player, as part of its global push. Rest-of-world revenue surged 969% to $78.2 million, according to Stocktwits — though that's off a tiny base.

The Guidance Is Actually Optimistic

Here's what the stock-drop narrative buries: Hims raised its full-year guidance.

Full-year 2026 revenue is now projected at $2.8 billion to $3.0 billion, up from prior guidance around $2.7–$2.9 billion. Adjusted core profit guidance sits at $275 million to $350 million, according to Stocktwits and MarketBeat.

For Q2, the company guided to revenue of $680 million to $700 million. That's a meaningful sequential jump from Q1's $608 million.

Long-term, Dudum and Okupe are holding to their 2030 targets: $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. Whether that's realistic depends entirely on whether the Novo Nordisk partnership delivers volume, and whether Amazon — which just entered the GLP-1 space — doesn't eat their lunch first.

TrustFinance noted management is forecasting a return to GAAP profitability in 2027.

What the Coverage Is Missing

Most financial coverage is treating this as a straightforward earnings miss. It's more complicated than that.

The $92 million GAAP loss was largely self-inflicted and intentional. The company had $751 million in cash and short-term investments at quarter's end and generated $53 million in free cash flow, according to MarketBeat. This is not a company running out of money.

What mainstream outlets are underplaying: the competitive threat from Amazon's GLP-1 entry and the question of whether Hims can maintain pricing power when a trillion-dollar retailer enters the same market. MarketBeat flagged this directly — Amazon's move into GLP-1 distribution is a serious wildcard that the bullish guidance from Dudum doesn't fully address.

Also underreported: the legal settlement. Hims paid $15 million to resolve legal issues tied to its branded GLP-1 expansion. The sources don't name who sued or why. That's a hole in the public record worth watching.

What Comes Next

Hims is paying a real price to clean up its act — dumping a legally murky compounded drug business and trying to build something sustainable with a legitimate pharma partner. The Q1 numbers look ugly because the company chose to take the pain now.

But raising guidance while posting a $92 million loss requires trusting management's execution. Dudum's track record on bold predictions is mixed. The Novo Nordisk bet could pay off big. Or Amazon could commoditize the entire space before Hims reaches scale.

Investors holding HIMS stock got a 13% haircut after-hours on May 11. That's the cost of being along for a high-risk pivot.